This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
ILD and respiratory illness in diseases classified elsewhere
ILD_ELSEWHERE
interstitial lung disease: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of pulmonary alveoli that extends to the interstitium and beyond leading to diffuse pulmonary fibrosis. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditions
|
474 |
3. Check pre-conditions, main-only, mode, registry filtersNone 0 out of 7 registries used, show all original rules. |
0 |
4. Check minimum number of eventsNone |
0 |
5. Include endpoints |
170 |
6. Filter based on genotype QC (FinnGen only) |
170 |
Control definitions (FinnGen only)
- Control exclude
- ILD_ENDPOINTS
- Control conditions
- not RESP_ILL_DIS_CLASS_ELSEWHERE
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
ILD and respiratory illness in diseases classified elsewhere
based on the number of shared cases.
Similar with more cases:
- Respiratory disorders in diseases classified elsewhere
- Interstitial lung disease
- Interstitial lung disease endpoints
- Other interstitial pulmonary diseases
- Respiratory diseases principally affecting the interstitium, IBD co-morbidites
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No data for upset plot.
No data for upset table.
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 759 | 447 | 310 |
| Only index persons | 620 | 367 | 253 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 66.31 | 66.49 | 66.17 |
| Only index persons | 66.16 | 66.01 | 66.39 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 170 | 99 | 71 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 63.44 | 62.30 | 65.04 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 149
- Matched controls
- 1488
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
+∞
94.0
80
*
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
+∞
89.9
77
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
49.4
85.2
115
95
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
91.3
77.4
83
20
P01BA02
ATC
hydroxychloroquine; oral
37.8
67.7
91
59
L04AX01
ATC
azathioprine; systemic
62.2
66.8
77
25
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
+∞
54.6
49
*
H02AB06
ATC
prednisolone; systemic
26.0
46.1
139
519
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
57.8
45.8
53
14
UGC12
NOMESCO Finland
Flexible bronchoscopy
22.4
44.9
69
55
J99.0*M05.1
ICD-10 Finland
Rheumatoid lung disease
+∞
44.0
40
*
TGC00
NOMESCO Finland
Bronchial lavation
84.8
43.3
47
8
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
20.8
42.5
67
56
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
23.8
41.2
61
42
L04AA06
ATC
mycophenolic acid; systemic
70.8
40.4
45
9
J99.1
ICD-10 Finland
Respiratory disorders in other diffuse connective tissue disorders
+∞
38.2
35
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
10.1
35.9
113
353
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
19.2
35.2
56
45
J18.9
ICD-10 Finland
Pneumonia, unspecified
8.4
30.9
91
235
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
50.2
29.6
35
9
GD1AA
NOMESCO Finland
Thorax X-ray examination
7.6
27.3
116
472
XG410
NOMESCO Finland
Flow-volume spirometry
19.8
26.2
40
27
J99.1*M35.0
ICD-10 Finland
Respiratory disorders in sicca syndrome [Sjögren]
+∞
25.8
24
*
J99.0
ICD-10 Finland
Rheumatoid lung disease
+∞
25.8
24
*
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
12.3
25.5
49
57
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
9.9
24.5
54
81
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
54.5
23.3
27
6
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
10.8
20.9
42
52
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
15.4
20.4
34
28
A07EC01
ATC
sulfasalazine; oral, rectal
8.9
19.4
44
67
J99.1*M31.3
ICD-10 Finland
Respiratory disorders in Wegener's granulomatosis
+∞
19.2
18
*
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
19.2
18
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
5.4
18.8
72
221
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
17.8
18.0
28
19
M33.2
ICD-10 Finland
Polymyositis
203.2
17.9
18
*
R06.0
ICD-10 Finland
Dyspnoea
5.0
17.9
75
251
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
8.4
17.3
40
62
J01MA14
ATC
moxifloxacin; systemic
8.3
17.1
40
63
L04AA13
ATC
leflunomide; oral
20.2
16.3
24
14
M05.9
ICD-10 Finland
Seropositive rheumatoid arthritis, unspecified
22.4
16.1
23
12
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
10.0
16.1
33
41
GD1AD
NOMESCO Finland
Thorax CT examination
12.8
14.2
25
23
M34.9
ICD-10 Finland
Systemic sclerosis, unspecified
+∞
13.8
13
*
R50.9
ICD-10 Finland
Fever, unspecified
5.2
13.1
44
110
ZX120
NOMESCO Finland
Intravenous
6.4
13.0
36
71
M31.3
ICD-10 Finland
Wegener granulomatosis
76.6
12.8
14
*
M33.1
ICD-10 Finland
Other dermatomyositis
+∞
12.7
12
*
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
12.7
12
*
L88
ICPC
Rheumatoid/seropositive arthritis
11.6
12.5
23
23
M05BA04
ATC
alendronic acid; oral
5.4
12.5
40
94
TPH04
NOMESCO Finland
Cathetrisation of vein
4.1
12.2
57
197
J96.1
ICD-10 Finland
Chronic respiratory failure
18.4
12.0
18
11
J01MA12
ATC
levofloxacin; systemic
4.0
11.8
55
189
J99.1*M34.8
ICD-10 Finland
Respiratory disorders in systemic: sclerosis
+∞
11.6
11
*
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
4.1
11.3
50
163
ND2BA
NOMESCO Finland
Hand and fingers extensive X-ray examination
17.2
11.1
17
11
L04AA01
ATC
[U] ciclosporin; systemic
30.6
10.9
14
5
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
5.7
10.8
32
68
L04AD01
ATC
ciclosporin; systemic
15.8
10.8
17
12
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
10.0
10.7
21
24
M05.1
ICD-10 Finland
Rheumatoid lung disease
+∞
10.5
10
*
J99.1*M32.1
ICD-10 Finland
Respiratory disorders in systemic: lupus erythematosus
+∞
10.5
10
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
6.4
10.5
28
52
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
11.9
10.1
18
17
C03CA01
ATC
furosemide; systemic
3.3
9.8
64
280
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.9
9.7
33
82
H04.10
ICD-10 Finland
Dry eye syndrome
5.0
9.7
32
77
TND11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in joint, wrist or hand
19.1
9.6
14
8
GD1CD
NOMESCO Finland
Thorax extensive CT-examination
106.5
9.5
10
*
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
106.5
9.5
10
*
GDA11
NOMESCO Finland
Thoracoscopic biopsy of lung
+∞
9.5
9
*
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
8.4
9.3
20
27
XQ858
NOMESCO Finland
Oxygen partial pressure measurement
25.9
9.1
12
5
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.9
9.0
40
128
WZC30
NOMESCO Finland
Teaching
4.2
8.7
35
102
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
2.8
8.7
84
465
TFC00
NOMESCO Finland
Catheterisation of right atrium or ventricle
17.6
8.7
13
8
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
21.6
8.6
12
6
J01AA02
ATC
doxycycline; systemic
4.0
8.5
132
987
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
11.8
8.5
15
14
GX1K5
NOMESCO Finland
Diffusion capacity
+∞
8.4
8
*
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
6.6
8.0
20
34
NH3EA
NOMESCO Finland
Feet X-ray examination with load
10.3
8.0
15
16
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
11.7
8.0
14
13
M34.0
ICD-10 Finland
Progressive systemic sclerosis
47.5
7.8
9
*
M01CB01
ATC
sodium aurothiomalate; parenteral
19.6
7.7
11
6
H26.3
ICD-10 Finland
Drug-induced cataract
84.1
7.5
8
*
M34.8
ICD-10 Finland
Other forms of systemic sclerosis
84.1
7.5
8
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.8
7.5
61
297
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
7.3
7
*
J17.3*B59
ICD-10 Finland
Pneumonia due to Pneumocystis carinii
+∞
7.3
7
*
M31.8
ICD-10 Finland
Other specified necrotizing vasculopathies
+∞
7.3
7
*
H02AB07
ATC
prednisone; oral
3.4
7.3
37
131
M80.4
ICD-10 Finland
Drug-induced osteoporosis with pathological fracture
21.3
7.2
10
5
R28
ICPC
Limited function/disability (R)
31.7
7.2
9
*
ZX108
NOMESCO Finland
Inhalation
31.7
7.2
9
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.5
7.0
34
117
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
4.3
6.8
25
67
SPAT1255
SPAT
Intravenous administration of medicine
5.6
6.8
19
38
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.0
6.8
44
185
R05
ICD-10 Finland
Cough
3.0
6.7
43
177
Z01.8
ICD-10 Finland
Other specified special examinations
2.8
6.6
48
214
R03AC02
ATC
salbutamol; inhalant
2.5
6.5
91
581
SPAT1083
SPAT
Initiation and monitoring of IV fluid therapy
6.5
6.5
16
27
M35.8
ICD-10 Finland
Other specified systemic involvement of connective tissue
72.8
6.5
7
*
M05BA07
ATC
risedronic acid; oral
7.6
6.4
14
20
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
19.0
6.3
9
5
L01AA01
ATC
cyclophosphamide; systemic
28.0
6.3
8
*
M34.1
ICD-10 Finland
CR(E)ST syndrome
28.0
6.3
8
*
Z94.2
ICD-10 Finland
Lung transplant status
+∞
6.3
6
*
GX1D5
NOMESCO Finland
Flow volume spirometry
+∞
6.3
6
*
J84.0
ICD-10 Finland
Alveolar and parietoalveolar conditions
+∞
6.3
6
*
A02BC02
ATC
pantoprazole; systemic
2.5
6.2
109
774
XG466
NOMESCO Finland
Sleep oxymetry
6.3
6.0
15
26
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
64
43
23.27
76.68
3.5
1.6
—
—
—
0
0
49
25
27.13
65.85
1.5
1.2
25.7
—
u/ml
—
10
0
39
11
45.71
63.58
2.6
1.5
—
—
—
0
0
50
29
24.01
63.52
1.5
1.2
52.2
—
u/ml
—
6
0
57
47
17.74
60.53
2.8
1.2
1.2
1.2
g/l
0.13
57
47
54
51
15.05
52.51
3.8
2.4
—
—
—
0
0
39
26
19.17
45.74
2.1
1.7
—
—
—
0
0
33
16
25.35
44.56
1.5
1.3
8.0
—
u/ml
—
5
0
35
22
19.77
42.11
2.1
1.7
—
—
—
0
0
90
219
7.61
39.64
2.9
2.0
—
—
—
0
0
42
42
12.95
38.78
1.8
1.6
1.2
0.1
iu/ml
—
14
9
37
33
14.05
36.62
2.2
1.3
—
—
—
0
0
39
38
13.02
36.52
2.7
1.6
—
—
—
0
0
38
36
13.31
36.21
2.6
1.6
—
—
—
0
0
28
19
17.45
32.12
1.7
1.8
—
—
—
0
0
31
27
13.82
30.92
18.5
6.2
166.8
156.6
iu/ml
—
5
5
29
23
15.00
30.54
1.7
1.7
—
—
—
0
0
68
158
6.51
30.32
2.3
1.9
—
—
—
0
0
68
161
6.37
29.65
2.5
2.0
—
—
—
0
0
26
18
16.87
29.43
1.3
1.1
—
—
—
0
0
30
28
12.80
28.59
2.6
1.6
—
—
—
0
0
109
419
5.46
26.52
7.5
2.0
101.1
214.0
u/l
1.85
104
399
80
240
5.41
26.31
1.5
1.3
105.6
38.0
iu/ml
1.13
44
78
74
230
4.93
22.81
1.4
1.3
54.6
11.9
u/ml
1.40
27
85
62
168
5.24
22.56
10.0
7.0
1.7
1.1
mmol/l
0.49
50
138
18
10
20.01
22.40
3.6
2.1
—
—
—
0
0
23
21
12.51
22.02
3.2
1.4
—
—
—
0
0
161
1053
10.98
21.11
22.5
4.2
21.5
12.0
mm/h
7.85
161
961
38
70
6.70
20.87
8.0
3.3
2.0
2.2
mmol/l
0.12
31
52
23
24
10.93
20.13
4.1
4.9
63.6
60.3
%
0.40
23
24
25
30
9.60
19.79
2.8
1.5
394.3
—
titre
—
7
0
22
24
10.38
18.62
4.1
4.2
4.7
5.2
e9/l
0.33
22
24
19
17
12.46
18.31
3.2
1.3
—
—
—
0
0
131
703
4.76
18.05
11.2
6.6
1.2
1.2
mmol/l
1.29
116
588
114
563
4.11
17.46
3.6
2.2
79.9
77.8
nmol/l
0.38
109
495
17
15
12.48
16.46
1.8
1.9
—
—
—
0
0
17
15
12.48
16.46
1.8
1.9
—
—
—
0
0
17
15
12.48
16.46
1.8
1.9
—
—
—
0
0
119
636
3.90
15.53
11.1
5.9
1.2
1.2
mmol/l
2.72
114
576
126
702
4.07
15.38
8.3
3.8
0.0
0.0
estimate
0.00
40
150
127
719
4.03
14.96
8.3
3.7
0.0
0.0
estimate
0.00
40
144
126
710
3.99
14.94
10.7
4.9
0.0
0.0
estimate
0.00
39
149
16
15
11.67
14.87
2.2
2.1
—
—
—
0
0
22
32
7.75
14.80
1.8
1.2
—
—
—
0
0
40
105
4.67
14.61
13.1
6.7
8.9
9.6
mmol/l
0.41
40
98
107
560
3.46
13.87
5.7
3.9
58.1
29.2
ng/l
0.96
93
402
16
17
10.29
13.65
2.3
2.0
—
—
—
0
0
22
36
6.87
13.29
2.2
1.3
—
—
—
0
0
17
6
31.22
13.24
1.9
1.3
—
—
—
0
0
12
10
12.84
11.86
2.4
1.5
—
—
—
0
0
158
1130
6.64
11.66
24.2
7.3
70.0
78.2
u/l
2.72
158
1050
16
21
8.31
11.62
1.2
1.2
1.7
1.3
u/ml
—
6
6
14
16
9.45
11.28
1.4
1.2
—
—
—
0
0
14
16
9.45
11.28
1.4
1.2
—
—
—
0
0
12
11
11.66
11.18
1.3
1.2
—
—
—
0
0
14
5
30.28
10.91
1.4
1.0
—
—
—
0
0
14
17
8.88
10.77
1.4
1.2
—
—
—
0
0
14
17
8.88
10.77
1.4
1.2
—
—
—
0
0
14
17
8.88
10.77
1.4
1.2
—
—
—
0
0
12
12
10.68
10.56
2.8
1.3
—
—
—
0
0
11
10
11.69
10.26
1.8
1.7
—
—
—
0
0
11
10
11.69
10.26
1.8
1.7
—
—
—
0
0
11
10
11.69
10.26
1.8
1.7
—
—
—
0
0
11
10
11.69
10.26
1.8
1.7
—
—
—
0
0
21
44
5.30
9.83
3.1
2.1
—
—
—
0
0
93
519
2.75
9.58
9.1
2.9
—
—
—
0
0
13
17
8.20
9.41
2.7
4.4
—
—
—
0
0
15
24
6.76
9.16
1.2
1.2
1.7
5.6
u/ml
—
7
12
11
12
9.73
9.08
1.0
1.2
—
—
—
0
0
77
399
2.70
9.07
9.6
4.0
0.0
0.0
estimate
0.00
40
142
16
28
6.20
8.98
2.9
2.4
14.9
16.9
%
—
8
13
27
75
4.09
8.98
2.0
2.0
—
—
—
0
0
23
58
4.43
8.65
1.5
2.4
—
—
—
0
0
23
58
4.43
8.65
1.5
2.4
3.7
3.7
g/l
0.00
15
48
23
58
4.43
8.65
1.5
2.4
7.8
7.3
g/l
0.46
16
49
19
41
5.09
8.58
2.6
2.0
—
—
—
0
0
63
303
2.71
8.51
2.2
1.7
1.6
1.3
mg/l
0.19
53
246
31
101
3.53
8.20
1.8
1.5
—
—
—
0
0
15
27
6.00
8.18
10.2
3.3
5.1
5.0
kpa
0.18
15
27
10
11
9.60
8.16
1.2
1.1
—
—
—
0
0
12
8
16.01
7.84
2.4
1.4
—
—
—
0
0
12
8
16.01
7.84
2.4
1.4
—
—
—
0
0
19
45
4.63
7.70
1.2
4.7
45.9
51.8
mg/l
0.19
14
35
19
45
4.63
7.70
1.2
4.7
74.9
28.5
mg/l
0.57
14
35
41
165
2.96
7.65
28.5
22.0
1.4
1.3
inr
—
7
21
92
552
2.45
7.62
9.5
3.8
—
—
—
0
0
35
129
3.16
7.60
3.7
3.6
3.2
2.1
mmol/l
0.86
28
102
16
33
5.25
7.57
3.1
1.9
122.6
129.8
g/l
—
9
23
45
193
2.81
7.47
3.4
2.4
17.2
23.6
%
3.26
40
166
82
475
2.40
7.25
5.1
3.1
2.3
2.4
mmol/l
2.16
77
419
10
5
21.11
7.22
3.0
1.6
62.5
63.8
ug/l
—
10
5
10
13
8.11
7.19
1.4
1.1
—
—
—
0
0
73
404
2.41
7.12
7.1
2.9
0.5
0.5
e6/l
0.02
66
292
20
53
4.14
7.04
1.5
2.6
3.1
3.1
g/l
0.05
15
48
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
17
42
4.39
6.53
7.9
2.2
0.4
0.4
u/ml
—
10
20
24
82
3.24
5.85
20.8
7.0
26.1
25.0
mmol/l
0.62
24
82
30
118
2.87
5.76
4.7
2.6
61.3
61.9
ml/min/173m2
0.03
13
48
17
48
3.82
5.48
1.4
1.1
—
—
—
0
0
14
35
4.27
5.28
1.1
1.1
—
—
—
0
0
8
7
11.91
4.83
1.5
2.0
—
—
—
0
0
8
7
11.91
4.83
1.5
2.0
—
—
—
0
0
8
7
11.91
4.83
1.5
2.0
—
—
—
0
0
54
304
2.14
4.74
1.3
1.2
0.7
1.6
u/ml
0.74
20
88
16
48
3.58
4.74
1.4
1.1
—
—
—
0
0
12
29
4.38
4.71
1.4
1.2
—
—
—
0
0
12
29
4.38
4.71
1.4
1.2
—
—
—
0
0
29
127
2.55
4.51
3.2
2.3
9.6
9.4
ug/l
0.02
24
118
11
26
4.45
4.43
1.6
1.5
—
—
—
0
0
9
12
7.85
4.41
1.7
1.5
—
—
—
0
0
44
242
2.10
4.04
4.5
2.5
0.6
1.1
e6/l
1.48
34
125
31
148
2.34
4.00
4.8
3.1
—
—
—
0
0
13
39
3.53
3.84
1.3
1.3
—
—
—
0
0
20
79
2.74
3.79
1.7
1.2
—
—
—
0
0
9
16
5.87
3.71
1.2
1.3
—
—
—
0
0
18
68
2.84
3.70
4.2
2.4
1.5
1.1
%
0.72
18
68
13
41
3.35
3.58
1.6
2.1
—
—
—
0
0
9
17
5.52
3.56
1.8
1.4
—
—
—
0
0
91
661
1.81
3.55
6.0
3.9
—
—
—
0
0
11
32
3.61
3.39
1.0
1.6
—
—
—
0
0
101
766
1.78
3.33
3.1
2.7
—
—
—
0
0
18
73
2.64
3.25
1.4
1.2
—
—
—
0
0
8
16
5.19
3.09
1.0
1.9
—
—
—
0
0
8
16
5.19
3.09
1.0
1.9
—
—
—
0
0
8
16
5.19
3.09
1.0
1.9
—
—
—
0
0
8
16
5.19
3.09
1.0
1.9
—
—
—
0
0
9
21
4.46
3.04
1.2
1.1
—
—
—
0
0
8
17
4.88
2.95
1.0
1.9
—
—
—
0
0
8
17
4.88
2.95
1.0
1.9
—
—
—
0
0
6
9
6.86
2.89
1.0
1.3
—
—
—
0
0
5
6
8.54
2.76
3.4
9.2
—
—
—
0
0
162
1500
2.70
2.50
49.9
17.0
80.4
77.6
umol/l
0.65
162
1500
42
266
1.77
2.47
2.5
2.6
2.5
2.5
mmol/l
0.03
37
230
10
34
3.06
2.45
1.1
1.3
—
—
—
0
0
137
1189
1.78
2.33
49.0
17.7
14.7
13.7
%
8.92
137
1166
11
41
2.80
2.32
1.0
1.1
—
—
—
0
0
8
24
3.44
2.21
1.1
1.2
—
—
—
0
0
162
1512
2.52
2.09
33.7
10.4
25.1
25.0
u/l
0.01
162
1451
6
15
4.10
2.05
1.0
1.2
—
—
—
0
0
144
1291
1.75
1.89
5.5
4.8
1.9
2.0
mu/l
0.14
139
1160
158
1464
2.12
1.76
43.3
16.4
139.3
139.8
mmol/l
1.73
158
1419
5
13
3.93
1.72
1.0
1.0
—
—
—
0
0
45
318
1.56
1.71
3.2
2.3
—
—
—
0
0
158
1469
2.07
1.66
43.3
16.5
4.0
4.0
mmol/l
0.50
158
1423
8
33
2.49
1.56
1.6
1.3
—
—
—
0
0
32
214
1.61
1.53
3.2
2.0
30.5
29.2
s
0.83
32
208
69
561
1.39
1.25
2.1
2.0
97.3
97.1
pmol/l
0.01
47
263
32
225
1.52
1.24
6.4
2.7
2.2
3.0
e6/l
0.22
22
111
105
931
1.33
1.02
5.2
2.9
85.2
47.6
u/l
0.56
100
863
5
23
2.21
0.98
1.0
1.1
—
—
—
0
0
162
1564
1.76
0.87
64.0
21.0
129.3
135.6
g/l
6.74
162
1538
48
394
1.30
0.78
1.7
1.7
1.5
1.3
mmol/l
1.91
42
334
6
34
1.79
0.77
1.0
1.3
—
237.1
—
0
10
26
197
1.38
0.71
1.4
1.4
—
—
—
0
0
6
105
0.56
0.64
2.2
1.7
—
—
—
0
0
21
264
0.77
0.49
3.2
3.2
0.6
0.8
ug/l
0.95
15
167
7
47
1.51
0.48
1.0
1.3
—
—
—
0
0
140
1344
1.24
0.44
36.6
13.7
78.2
78.8
ml/min/173m2
0.10
131
1099
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.0
—
0.9
—
0
6
120
1256
0.85
0.40
40.2
15.3
39.4
39.8
%
0.34
71
901
135
1390
0.86
0.29
5.1
4.7
5.7
6.0
mmol/l
2.28
126
1265
12
95
1.28
0.27
1.0
2.0
—
—
—
0
0
132
1357
0.88
0.25
4.4
4.1
1.4
1.3
mmol/l
2.45
126
1234
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
451.8
—
0
8
0
13
0.00
0.21
0.0
1.1
—
41.9
—
0
8
0
14
0.00
0.20
0.0
2.0
—
—
—
0
0
137
1398
0.90
0.18
4.7
4.6
1.4
1.5
mmol/l
1.20
128
1279
32
347
0.90
0.16
3.8
4.9
23.9
21.5
%
0.39
18
171
12
135
0.88
0.10
1.6
2.5
36.6
30.2
u/l
0.75
12
110
7
63
1.12
0.08
1.4
1.0
—
—
—
0
0
139
1406
0.94
0.08
4.7
4.7
4.5
4.7
mmol/l
1.68
129
1295
9
85
1.06
0.07
1.0
1.9
—
—
—
0
0
18
171
1.06
0.03
10.8
8.4
—
—
—
0
0
20
191
1.05
0.03
1.6
1.4
—
—
—
0
0
143
1439
0.96
0.03
5.1
5.2
2.6
2.7
mmol/l
1.37
132
1316
44
436
1.01
0.00
3.7
5.3
1.6
3.0
ug/l
1.07
38
381
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
4.8
—
60.3
—
0
5
0
9
0.00
0.00
0.0
3.6
—
1041.4
—
0
9
0
5
0.00
0.00
0.0
1.0
—
0.3
—
0
5
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint ILD_ELSEWHERE and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ILD_ELSEWHERE | 3.489 [2.71, 4.5] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.353 |
During the follow-up period (1.1.1998 — 31.12.2019), 146 out of 355 females with ILD_ELSEWHERE died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| ILD_ELSEWHERE | 3.206 [2.23, 4.61] | < 0.001 |
| Birth year | 0.987 [0.98, 1.0] | 0.009 |
During the follow-up period (1.1.1998 — 31.12.2019), 110 out of 242 males with ILD_ELSEWHERE died.
Mortality risk
Mortality risk for people of age
years, who have ILD_ELSEWHERE.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.286% | 0.576% |
| 5 | 2.039% | 3.501% |
| 10 | 5.545% | 8.929% |
| 15 | 10.315% | 17.278% |
| 20 | 17.819% | 28.56% |
Relationships between endpoints
↥Index endpoint: ILD_ELSEWHERE – ILD and respiratory illness in diseases classified elsewhere
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data